Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older - Concepedia

Concepedia

Publication | Open Access

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

DOI Full Paper Access

70

Citations

21

References

2021

Year

Lucie Obéric, Frédéric Peyrade, Mathieu Puyade, Christophe Bonnet, Peggy Dartigues-Cuillères, Bettina Fabiani, Philippe Ruminy, Hervé Maisonneuve, Julie Abraham, Catherine Thiéblemont,

Journal of Clinical Oncology

Abstract

The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population.

References

	Year	Citations

Page 1